#LSBCmember NEWS: United Therapeutics Corporation Announces Successful World’s First UKidney Transplant Read more here: https://lnkd.in/eC37XHYf
Life Sciences BC’s Post
More Relevant Posts
-
Wrapping up the 19th Annual HD Therapeutics Conference 2024 with enlightening insights! Here's a brief recap from the final day of the conference. Stay tuned for more updates! #HDResearch #HuntingtonsDisease #ScientificAdvancements #HDAfrica
-
-
Achieving Next-Generation mRNA-LNP Therapeutics Delivery https://lnkd.in/e_H8yJEJ Three LNP experts (Dr. Kate Zhang, Professor Ben Muir, and Dr. Sumit Luthra) parse out the current opportunities and unknowns facing the development of next-generation LNPs.
-
-
#News: VYNE Therapeutics has completed enrollment in a Phase 2b trial evaluating VYN201 for the treatment of nonsegmental #vitiligo. Read more: https://bit.ly/4gF1Y43
-
-
PRISM MarketView interviewed Cardiol Therapeutics Inc. CEO David Elsley to discuss the company’s pivotal Phase III MAVERIC trial and the significant commercial potential of CardiolRx™. https://lnkd.in/etrfgExZ
-
-
Do you want an update on what's been happening at Argenica Therapeutics? This morning, we released our most recent Investor Presentation, providing an update on our Phase 2 Clinical Trial. Read the full presentation here➡️ https://bit.ly/4f4NZ70 #clinicaltrial #investorupdate #AGN #ASX #stroke #strokeawareness
-
-
Chief & Director, Cellular Therapy Program. Associate Professor, Children's National & GWU | Cell Therapy Expert | Speaker | Leader
Great to see some positive news in the allogeneic CAR T space. Especially for a disease like Multiple Myeloma where commercial companies have struggled to meet demand. Also interest to see prominent use of a non-viral gene delivery platform, which I think we'll see more of very soon. #CART #celltherapy #genetherapy.
VP Business Development | Cell & Gene Therapy Enthusiast | Liverpool FC Fan | @markflower@bsky.social
More positive #CARTcellTherapy news for #MultipleMyeloma patients as Poseida Therapeutics, Inc. and Roche's allogeneic product advances in clinical setting with a reported 91% ORR in 23 patients. (From geneng news) https://lnkd.in/guDcJxjP
-
-
Exciting discussions yesterday around biotherapy processes! With Cécile Bonvoisin - Hemab Therapeutics, we have presented our approach to ensure phase 3 readiness while transferring at a new CDMO and considering process optimization and comparability challenges. Thanks a lot to A3P Association for organizing this congress and to all the attendees for the fruitful discussions. Merck Life Science #CDMO #comparability #techtranfer
-
-
Biotech Initiates Phase III Trial for Heart Disease Drug: https://ow.ly/vMx450Ubokc Clinical-stage life sciences company Cardiol Therapeutics Inc. is setting up a phase III trial for its pericarditis drug, CardioRx, after pilot study sees success. Read why analysts like this biotech stock. $CRDL #biotechstocks
-
Small molecule #therapeutics have had a powerful impact on patients for generations. As #synbio-derived therapeutics offer a new generation of #medicine, what does this mean for small molecule modalities? Join the discussion at #SynBioBeta2024: https://lnkd.in/eShayXpi
-
